Renal Cell Carcinoma in a Patient with Rheumatoid Arthritis Treated with Adalimumab

ISSN: 2212-3911 (Online)
ISSN: 1574-8863 (Print)

Volume 12, 3 Issues, 2017

Download PDF Flyer

Current Drug Safety

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Dr. Seetal Dodd
University of Melbourne
Geelong, 3220

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Renal Cell Carcinoma in a Patient with Rheumatoid Arthritis Treated with Adalimumab

Current Drug Safety, 9(1): 69-72.

Author(s): Senol Kobak, Ahmet Karaarslan and Yunus Aktakka.

Affiliation: Department of Rheumatology, Faculty of Medicine, Sifa University, 35100-Bornova/Izmir-Turkey.


Rheumatoid arthritis (RA) is a chronic erosive inflammatory disease which can involve the locomotor system and cause systemic involvement. The efficacy and safety of anti-TNF-alpha drugs have been shown in active RA cases that are resistant to traditional disease-modifying antirheumatic drugs. However, it is well known that anti-TNF-alpha drugs may cause lymphomas and various solid malignancies. On the other hand, there are studies on the efficacy of anti- TNF-alpha drugs in the treatment of resistant renal cell cancer. This case report presents a 57-year-old female patient with hematuria who had been followed up with the diagnosis of RA for 20 years and had been using adalimumab for the last 4 years. A solid mass was found in the left kidney in the abdominal ultrasonography and computed tomography. Nephrectomy was performed by general surgery. Histopathological findings of the specimen were consistent with renal cell carcinoma.


Adalimumab, renal cell carcinoma, rheumatoid arthritis.

Download Free Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 9
Issue Number: 1
First Page: 69
Last Page: 72
Page Count: 4
DOI: 10.2174/15748863113086660063

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science